<DOC>
	<DOCNO>NCT02985255</DOCNO>
	<brief_summary>Patients enrol study , eligible NACT , undergo pre-treatment workup comprise Evaluation Under Anesthesia ( EUA ) tumor Mapping tissue biopsy along PET-CT scan . Subsequently , would undergo 3 cycle NACT ( weekly thrice ) DCF . They would reassess PET-CT EUA +/- biopsy end third cycle . Those achieve CR would undergo adjuvant CTRT . Subjects PR PET-CT scan re-classified base biopsy report . If remain PR group undergo surgery biopsy negative malignancy , undergo adjuvant CTRT . Those subject SD PD would undergo surgery . Subsequently , radiation and/ chemotherapy decide base final histopathology ( surgical specimen ) report . PET-CT EUA +/- HPE analysis would repeat follow-up 3 month treatment completion .</brief_summary>
	<brief_title>Role Neo-adjuvant Chemotherapy Tongue Preservation Locally Advanced Squamous Cell Carcinoma Oral Tongue</brief_title>
	<detailed_description>Patients enrol study , eligible Neoadjuvant chemotherapy , undergo pre-treatment workup comprise Evaluation Under Anesthesia ( EUA ) tumor Mapping tissue biopsy along PET-CT scan . Subsequently , would undergo 3 cycle Neoadjuvant chemotherapy ( weekly thrice ) injection Docetaxel , Cisplatin , 5-FU . They would reassess PET-CT EUA +/- biopsy end third cycle . Those achieve Complete Response ( CR ) would undergo adjuvant chemo-radiotherapy . Subjects partial response ( PR ) PET-CT scan re-classified base biopsy report . If remain PR group undergo surgery . If biopsy patient negative malignancy , undergo adjuvant chemoradiotherapy . Those subject stable disease ( SD ) progressive disease ( PD ) would undergo surgery . Subsequently , radiation and/ chemotherapy decide base final histopathology ( surgical specimen ) report . PET-CT EUA +/- HPE analysis would repeat follow-up 3 month treatment completion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Tongue Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly diagnose squamous cell carcinoma ( well/ moderately/ poorly differentiate ) oral tongue ( anterior two third ) present Health Care Global Enterprises Ltd January 2016 March 2017 include study . Stage III stage IV ( T3 , 4 N03 , M 0 ) select case T2 advance nodal status also include study . Patients recurrence/ residual disease oral tongue . Patients receive alternative treatment evaluate NACT Patient fit NACT Patient able give consent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Tongue Malignancy</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
</DOC>